CMS Grants NTAP Status for ZEVASKYN to Enhance Reimbursement

Key Facts

In a move designed to support patient access to innovative therapies and ease the financial burden on healthcare facilities, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) status for ZEVASKYN. According to reports, this designation provides supplemental reimbursement for hospital inpatient settings to cover the higher costs associated with new medical technologies. The additional payment framework is scheduled to take effect starting in Fiscal Year 2027.

This regulatory development highlights the clinical significance of the gene therapy developed by Abeona Therapeutics, as NTAP status is reserved for technologies that offer meaningful benefits beyond standard hospital rates. The designation optimizes treatment center economics for ZEVASKYN, potentially clearing the path for broader commercial adoption within the U.S. healthcare market.

Looking ahead at the broader economic context, the sector remains sensitive to monetary policy; per market data from July 29, 2026, the Federal Reserve held interest rates at 3.75%, a key factor influencing the financing environment for biotechnology firms.